BAQSIMI DIN 02492415
Health Canada record
| Active ingredient(s) | GLUCAGON 3 MG |
|---|---|
| Dosage form | Powder |
| Route | Nasal |
| Schedule | ETHICAL |
| Class | Human |
| ATC | H04AA01 GLUCAGON |
| Original market date | 20-Nov-2019 |
| Current status date | 23-Sep-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Amphastar Pharmaceuticals, Inc. — licence 101197, currently licensed, last inspection rating C (2023-05-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GLUCAGON
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02568969 | LUPIN-GLUCAGON | LUPIN PHARMA CANADA LIMITED | Powder For Solution | GLUCAGON 1 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32701 | 2024-02-14 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 22694 | 2019-09-25 | New Drug Submission (NDS) |
International API supply for GLUCAGON
4 active FDA Drug Master Files.
Request a quote for BAQSIMI